

Amendments to the Specification:

Please replace the paragraph beginning at page 1, line 7, with the following rewritten paragraph:

-- This application is a divisional of U.S. Patent Application No. 09/469,655 filed December 22, 1999, which claims the benefit of U.S. Provisional Patent Application No. 60/119,972 filed February 12, 1999, the disclosures of which are [is] incorporated by reference. --

Please replace the paragraph beginning on page 9, line 11, with the following new paragraph:

-- Binding agents of the invention compete with exemplary antibodies designated MA~~b~~ 292-2-3 (ATCC HB-12645), MA~~b~~ 592-2-5 (ATCC-12646), MA~~b~~ 5-7-5 (ATCC-12647), MA~~b~~ 5-1-5 (ATCC HB-12649), MA~~b~~ 281-1-1 (ATCC HB-12648), MA~~b~~ 763-15-5 (ATCC []PTA-1079), and MA~~b~~ 763-15-20 (ATCC []PTA-1078), for specific binding to human cytochrome P450 2C family members. Production of monoclonal antibodies MA~~b~~ 292-2-3, MA~~b~~ 592-2-5, MA~~b~~ 5-7-5, MA~~b~~ 5-1-5, MA~~b~~ 281-1-1, MA~~b~~ 763-15-5, and MA~~b~~ 763-15-20 is described in the Examples. --

Please replace the paragraph beginning at page 11, line 4 with the following new paragraph:

--Hybridomas producing MA~~b~~ 292-2-3 (ATCC HB-12645), MA~~b~~ 592-2-5 (ATCC HB-12646), MA~~b~~ 5-7-5 (ATCCHB-12647), MA~~b~~ 5-1-5 (ATCC-HB 12649), MA~~b~~ 281-1-1 (ATCC HB-12[4]648), MA~~b~~ 763-15-5 (ATCC[]PTA-1079), and MA~~b~~ 763-15-20 (ATCC[]PTA-1078) have been deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 under the Budapest Treaty and given the Accession Nos. indicated. MA~~b~~ 292-2-3 (ATCC HB-12645), MA~~b~~ 592-2-5 (ATCC HB-12646), MA~~b~~ 5-7-5 (ATCCHB-12647), MA~~b~~ 5-1-5 (ATCC-HB 12649), MA~~b~~ 281-1-1 (ATCC HB-12648) were given the Accession Nos. indicated on February 3, 1999. MA~~b~~ 763-15-5 (ATCC PTA-1079), and MA~~b~~ 763-15-20 (ATCC PTA-1078) were given the Accession Nos. indicated on December 21, 1999. These cell lines will be maintained at an authorized depository and replaced in the event of mutation, nonviability or destruction for a period of at least five

years after the most recent request for release of a sample was received by the depository, for a period of at least thirty years after the date of the deposit, or during the enforceable life of the related patent, whichever period is longest. All restrictions on the availability to the public of these cell lines will be irrevocably removed upon the issuance of a patent from the application.--